PL2563403T3 - Koniugat czynnika krzepnięcia krwii viia i peg - Google Patents

Koniugat czynnika krzepnięcia krwii viia i peg

Info

Publication number
PL2563403T3
PL2563403T3 PL11719041T PL11719041T PL2563403T3 PL 2563403 T3 PL2563403 T3 PL 2563403T3 PL 11719041 T PL11719041 T PL 11719041T PL 11719041 T PL11719041 T PL 11719041T PL 2563403 T3 PL2563403 T3 PL 2563403T3
Authority
PL
Poland
Prior art keywords
conjugate
peg
blood coagulation
coagulation factor
factor viia
Prior art date
Application number
PL11719041T
Other languages
English (en)
Inventor
William Henry
Original Assignee
Cantab Biopharmaceuticals Patents Ltd
Polytherics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42289986&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2563403(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cantab Biopharmaceuticals Patents Ltd, Polytherics Ltd filed Critical Cantab Biopharmaceuticals Patents Ltd
Publication of PL2563403T3 publication Critical patent/PL2563403T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays or needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/006—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length of peptides containing derivatised side chain amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/113—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure
    • C07K1/1133—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure by redox-reactions involving cystein/cystin side chains
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
PL11719041T 2010-04-30 2011-04-28 Koniugat czynnika krzepnięcia krwii viia i peg PL2563403T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1007356.7A GB201007356D0 (en) 2010-04-30 2010-04-30 Conjugated factor VIIa
PCT/GB2011/000663 WO2011135308A1 (en) 2010-04-30 2011-04-28 Conjugated blood coagulation factor viia
EP11719041.3A EP2563403B1 (en) 2010-04-30 2011-04-28 Conjugate of blood coagulation factor viia and peg

Publications (1)

Publication Number Publication Date
PL2563403T3 true PL2563403T3 (pl) 2015-03-31

Family

ID=42289986

Family Applications (1)

Application Number Title Priority Date Filing Date
PL11719041T PL2563403T3 (pl) 2010-04-30 2011-04-28 Koniugat czynnika krzepnięcia krwii viia i peg

Country Status (28)

Country Link
US (1) US9309507B2 (pl)
EP (1) EP2563403B1 (pl)
JP (2) JP2013525415A (pl)
KR (1) KR20130055620A (pl)
CN (1) CN102971013B (pl)
AP (1) AP2012006574A0 (pl)
AU (1) AU2011247148B2 (pl)
CA (1) CA2796870A1 (pl)
CL (1) CL2012003038A1 (pl)
CO (1) CO6660500A2 (pl)
CR (1) CR20120580A (pl)
DK (1) DK2563403T3 (pl)
EA (1) EA201290941A1 (pl)
EC (1) ECSP12012315A (pl)
ES (1) ES2503570T3 (pl)
GB (2) GB201007356D0 (pl)
IL (1) IL222565A (pl)
MX (1) MX2012012684A (pl)
MY (1) MY160510A (pl)
NI (1) NI201200161A (pl)
NZ (1) NZ603938A (pl)
PE (1) PE20130253A1 (pl)
PH (1) PH12012502149A1 (pl)
PL (1) PL2563403T3 (pl)
RU (1) RU2012144554A (pl)
SG (1) SG184573A1 (pl)
WO (1) WO2011135308A1 (pl)
ZA (1) ZA201208988B (pl)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2101821E (pt) 2006-12-15 2014-10-03 Baxter Int Fator conjugado viia-ácido (poli)siálico com prolongamento do tempo de meia vida in vivo
US8642737B2 (en) 2010-07-26 2014-02-04 Baxter International Inc. Nucleophilic catalysts for oxime linkage
US8809501B2 (en) 2009-07-27 2014-08-19 Baxter International Inc. Nucleophilic catalysts for oxime linkage
ES2597954T3 (es) 2009-07-27 2017-01-24 Baxalta GmbH Conjugados de proteína de la coagulación sanguínea
JP5909755B2 (ja) 2009-07-27 2016-04-27 リポクセン テクノロジーズ リミテッド 非血液凝固タンパク質の糖ポリシアル酸化
EP3093029A1 (en) 2009-07-27 2016-11-16 Baxalta GmbH Blood coagulation protein conjugates
BR112013015898A2 (pt) 2010-12-22 2018-06-26 Baxter International Inc. derivado de ácido graxo solúvel em água, e, métodos para preparar um derivado de ácido graxo e uma proteína terapêutica conjugada.
MY190257A (en) 2012-04-16 2022-04-11 Cantab Biopharmaceuticals Patents Ltd Optimised subcutaneous therapeutic agents
US10231993B2 (en) 2013-06-27 2019-03-19 University Of Washington Through Its Center For Commercialization Biocompatible polymeric system for targeted treatment of thrombotic and hemostatic disorders
GB201417589D0 (en) * 2014-10-06 2014-11-19 Cantab Biopharmaceuticals Patents Ltd Pharmaceutical Formulations
GB201518171D0 (en) 2015-10-14 2015-11-25 Cantab Biopharmaceuticals Patents Ltd Colloidal particles for topical administration with therapeutic agent
GB201518170D0 (en) 2015-10-14 2015-11-25 Cantab Biopharmaceuticals Patents Ltd Colloidal particles for subcutaneous administration with intravenous administration of therapeutic agent
GB201518172D0 (en) 2015-10-14 2015-11-25 Cantab Biopharmaceuticals Patents Ltd Colloidal particles for use in medicine
KR20190086269A (ko) * 2018-01-12 2019-07-22 재단법인 목암생명과학연구소 체내 지속형 재조합 당단백질 및 이의 제조방법

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE504074C2 (sv) 1993-07-05 1996-11-04 Pharmacia Ab Proteinberedning för subkutan, intramuskulär eller intradermal administrering
US5643575A (en) 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
IL113010A (en) 1994-03-31 1999-10-28 Pharmacia & Upjohn Ab Pharmaceutical formulation comprising factor viii with an activity of at least 500iu/ml and an enhancer for improved subcutaneous intramuscular or intradermal administration
SE9503380D0 (sv) 1995-09-29 1995-09-29 Pharmacia Ab Protein derivatives
WO1998032466A1 (en) 1997-01-29 1998-07-30 Polymasc Pharmaceuticals Plc Pegylation process
CA2739933A1 (en) 2000-02-11 2001-08-16 Bayer Healthcare Llc Factor vii or viia-like molecules
CZ20032454A3 (en) * 2001-03-22 2004-03-17 Novo Nordisk Health Care Ag Coagulation factor vii derivative
US7235638B2 (en) 2001-03-22 2007-06-26 Novo Nordisk Healthcare A/G Coagulation factor VII derivatives
HK1080372A1 (zh) 2002-05-01 2006-04-28 Schering Aktiengesellschaft 作为抗凝剂的新型组织因子目标抗体
DE60336555D1 (de) 2002-06-21 2011-05-12 Novo Nordisk Healthcare Ag Pegylierte glykoformen von faktor vii
UA86744C2 (en) * 2002-06-21 2009-05-25 Ново Нордиск Хэлс Кеа Аг Pegylated factor vii glycoforms
US20040062748A1 (en) 2002-09-30 2004-04-01 Mountain View Pharmaceuticals, Inc. Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof
MXPA05007151A (es) * 2002-12-31 2005-09-21 Nektar Therapeutics Al Corp Polimeros terminados en maleimida hidroliticamente estables.
BRPI0407882B1 (pt) 2003-02-26 2021-07-27 Nektar Therapeutics Composição compreendendo conjugados de polímero-porção de fator viii e seu método de fabricação
GB0316294D0 (en) 2003-07-11 2003-08-13 Polytherics Ltd Conjugated biological molecules and their preparation
US20060198819A1 (en) 2003-08-08 2006-09-07 Novo Nordisk Healthcare A/G Use of galactose oxidase for selective chemical conjugation of protractor molecules to proteins of therapeutic interest
CA2571292C (en) 2004-06-30 2013-05-21 Nektar Therapeutics Al, Corporation Polymer-factor ix moiety conjugates
US20090176967A1 (en) 2004-08-02 2009-07-09 Novo Nordisk Healthcare A/G Conjugation of FVII
PT2363414T (pt) 2004-11-12 2022-08-04 Bayer Healthcare Llc Modificação de fviii direcionada a sítio
WO2006114105A2 (en) 2005-04-26 2006-11-02 Maxygen Holdings Ltd. Use of modified factor vii for treating bleeding
ES2553160T3 (es) 2005-06-17 2015-12-04 Novo Nordisk Health Care Ag Reducción y derivatización selectivas de proteínas Factor VII transformadas por ingeniería que comprenden al menos una cisteína no nativa
AU2007245190B2 (en) 2006-03-31 2011-07-21 Takeda Pharmaceutical Company Limited Pegylated factor VIII
WO2008025856A2 (en) 2006-09-01 2008-03-06 Novo Nordisk Health Care Ag Modified glycoproteins
PT2101821E (pt) 2006-12-15 2014-10-03 Baxter Int Fator conjugado viia-ácido (poli)siálico com prolongamento do tempo de meia vida in vivo
US8575397B2 (en) 2007-02-14 2013-11-05 Biocompatibles Uk Limited Derivatisation of biological molecules
CA2683443A1 (en) 2007-04-13 2008-10-23 Catalyst Biosciences, Inc. Modified factor vii polypeptides and uses thereof
CN101820920B (zh) 2007-10-09 2014-08-06 宝力泰锐克斯有限公司 新的缀合蛋白质和肽
DK2280734T3 (da) 2008-04-24 2014-05-26 Cantab Biopharmaceuticals Patents Ltd Faktor-ix-konjugater med forlængede halveringstider
AU2009275358C1 (en) 2008-07-21 2015-09-24 Polytherics Limited Novel reagents and method for conjugating biological molecules
WO2010033240A2 (en) 2008-09-19 2010-03-25 Nektar Therapeutics Carbohydrate-based drug delivery polymers and conjugates thereof
US20110171165A1 (en) 2008-09-19 2011-07-14 Nektar Therapeutics Polymer conjugates of opioid growth factor peptides
US20110171166A1 (en) 2008-09-19 2011-07-14 Nektar Therapeutics Polymer conjugates of osteocalcin peptides
DK2349341T3 (da) 2008-10-15 2014-01-06 Baxter Int Pegylering af rekombinante blodkoagulationsfaktorer i nærvær af bundne antistoffer
US20100099616A1 (en) 2008-10-17 2010-04-22 Baxter International Inc. Modified blood factors comprising a low degree of water soluble polymer
KR20110093775A (ko) 2008-11-03 2011-08-18 바이엘 헬스케어 엘엘씨 혈우병 치료 방법
GB0823309D0 (en) 2008-12-19 2009-01-28 Univ Bath Functionalising reagents and their uses
US20120121613A1 (en) 2009-01-19 2012-05-17 Bayer Healthcare Llc Protein conjugate having an endopeptidase- cleavable bioprotective moiety
GB0912485D0 (en) * 2009-07-17 2009-08-26 Polytherics Ltd Improved conjugation method
EP2536753B1 (en) 2010-02-16 2017-12-20 Novo Nordisk A/S Factor viii molecules with reduced vwf binding
PT2536399T (pt) 2010-02-21 2020-02-06 Bayer Healthcare Llc Método para ativação e conjugação de biomoléculas

Also Published As

Publication number Publication date
IL222565A0 (en) 2012-12-31
PE20130253A1 (es) 2013-03-16
EA201290941A1 (ru) 2013-04-30
CR20120580A (es) 2013-04-25
NI201200161A (es) 2013-04-19
JP2013525415A (ja) 2013-06-20
GB2492738A (en) 2013-01-09
GB201220669D0 (en) 2013-01-02
EP2563403A1 (en) 2013-03-06
WO2011135308A1 (en) 2011-11-03
CO6660500A2 (es) 2013-04-30
MX2012012684A (es) 2013-04-03
AU2011247148B2 (en) 2014-09-18
AP2012006574A0 (en) 2012-12-31
PH12012502149A1 (en) 2013-02-04
CL2012003038A1 (es) 2014-01-24
GB201007356D0 (en) 2010-06-16
NZ603938A (en) 2013-08-30
HK1175999A1 (en) 2013-08-23
RU2012144554A (ru) 2014-06-10
AU2011247148A1 (en) 2012-12-20
KR20130055620A (ko) 2013-05-28
ES2503570T3 (es) 2014-10-07
US20130129698A1 (en) 2013-05-23
EP2563403B1 (en) 2014-06-18
ZA201208988B (en) 2014-02-26
GB2492738A8 (en) 2014-03-05
MY160510A (en) 2017-03-15
CN102971013B (zh) 2015-01-07
ECSP12012315A (es) 2013-05-31
DK2563403T3 (da) 2014-09-15
US9309507B2 (en) 2016-04-12
IL222565A (en) 2015-10-29
JP2015110636A (ja) 2015-06-18
GB2492738B (en) 2014-05-21
CA2796870A1 (en) 2011-11-03
CN102971013A (zh) 2013-03-13
SG184573A1 (en) 2012-11-29

Similar Documents

Publication Publication Date Title
PL2563403T3 (pl) Koniugat czynnika krzepnięcia krwii viia i peg
IL294296A (en) Balloon endoscope and methods for its production and use
IL264200B (en) Flexible cushioning pads, items incorporating such pads, and methods of making and using
HRP20182102T1 (hr) Terapijski pripravci nukleaze i postupci
IL241985A0 (en) Enantiomers of spiro-oxindole compounds and their uses as therapeutic agents
EP2654578A4 (en) Disposable venous tourniquets and methods of use
DK2582314T3 (da) Intravascular arterial to venous anastomosis and tissue welding catheter
EP2605827A4 (en) NON-INVASIVE TREATMENT OF BRONCHOCONSTRICTION
EP2635185A4 (en) DETERMINATION OF OXYGENATION OF IN VIVO TISSUE
ZA201302251B (en) Tissue fixator
EP2710127A4 (en) SELECTIVE ULTRASONIC LYSE OF BLOOD AND OTHER BIOLOGICAL FLUIDS AND WOVEN
ZA201307641B (en) Human tissue factor antibody and uses thereof
FI20135146L (fi) Farmaseuttiset koostumukset ja hoitomenetelmät
IL226495A0 (en) Derivatives of heteroarylsulfonamides
PL3260128T3 (pl) Zastosowanie medyczne rozpuszczalnego CD24
PL2613798T3 (pl) Zastosowanie lizosomalnej kwaśnej lipazy do leczenia niedoboru lizosomalnej kwaśnej lipazy u pacjentów
IL207586A0 (en) A fibrin based therapeutic preparation and use thereof
EP2774596A4 (en) MEDICAL EXTENSION INSTRUMENT AND SET OF MEDICAL EXTENSION INSTRUMENTS
EP2614375A4 (en) COMBINATION METHOD FOR CANCER DIAGNOSIS
EP2545955A4 (en) MEDICAL NEEDLE AND STEEL INSTRUMENT
IL220738A0 (en) Arylsulfonamide pyridine-pyridinone derivatives, preparation of same, and therapeutic use thereof
EP2598164A4 (en) PERIPHERAL BLOOD SPARC ANTIBODIES AND USES THEREOF
ZA201304012B (en) Novel compound and medical use thereof
GB0920258D0 (en) New medical agents and use thereof
ME02992B (me) Intermedijeri agomelaтina i postupci njihove priprave